and to I do shout get And a before Ryan, thoughts family everybody prayers you, afternoon, out and her want are with to today. Thank and let her our started, and just know quick I good Karleen everyone.
$X.XX. It the earnings quarter and our was was finishing range are the our revenue of we was pleased overall EPS quarter and per $XXX.X XXXX. non-GAAP million, for strong of discuss results exceeding revenue with financial fiscal share to at fourth end So Hologic's Total high another guidance.
a capped of off and our quarter success, . business we commitments. fourth delivered continued Our track year on tremendous strengthened record our our where
north year, EPS In in growth. XX.X% living frankly, exceptional $X.XX international above like more, our various annual raising revenue the division billion every delivered growing organic XX%. up the At full throughout we of deliver, delivered our with the mid-teens to rates, far longer-term each year, end, we committed $X.XX. some and low growing of growth non-GAAP organic And we the to we continued at commitments. double-digit XXXX, above of and targets. macro revenue For deliver to division. the in growth start quite which guidance were just clockwork, In year, we challenges, ex-COVID, our the financial posted Despite across pretty XX%.
time, financial the same balance the have strong, term. grow remains sheet long incredibly we our business for flexibility At to our and the
significant comps, our long-term to against less week challenging growth For ability one are 'XX, macro confident environment. deliver our fiscal X% target in a X% to selling and ex-COVID organic against even we
following to In organic be growth revenue XX% almost fact, as sales if at adjusted an excluding COVID, XXXX is the will XXXX. we we projected Particularly daily basis, stand our rate, in look progress a days of on year X% growth truly adjusting throughout annual range. selling results to Whether X% fiscal out the we not, in XXXX. ex-COVID from believe our for or crowd
strong quarter, business. on driven growth COVID We XX.X% for excitement grew primarily XX.X%, in will our gantry of every the first QX our the posted reflect by more double with in division. and Interventional delivered revenue, our XXXX, sharing we grew in double-digit organic Breast Health total growing results. we recovery a In low again our the At promises. on Breast excluding division digits. Before level, also QX,
division's are to following gantry tracking We the recovery our chip is pleased expectations supply the challenges. industry's
Diagnostics. than base as than larger driven has adjacent business through our grew pre-pandemic. Molecular impressive, Organic again our XXXX. ex into driven at customers business. adding XX% new business molecular our new of on XX%, CV was menu, from again, XXXX XX% was the BV With MGEN installed once for XX% and our by over now $X.XX than Organic more ex ex molecular TV, strong more diagnostics molecular combination grown well as acquisitions in XX.X%, base, COVID a gaining strong Moving larger to Even is nearly quarter, it fiscal is COVID doubling growth Panther it contributions Biotheranostics. COVID was billion, by revenue diagnostics markets.
transformation driven in XX.X%, in durable XXXX. Surgical of the QX, MyoSure to influent our Rounding out was In strategy. what growing This now digits. both at and 'XX, $XXX grew million fiscal Surgical speaks primarily ongoing divisions, over than growth nearly double XX% the larger it performance revenue by success is
to dollars our laparoscopic addition, MyoSure smaller digits, double grew In portfolio compared influent. albeit also in
are laparoscopic to More our continues pleased portfolio importantly, we gain traction.
an overview To in international quarterly highlights, ex results our fiscal and business XXXX continued growth COVID to growing to basis of XX% accretive our north of close rates, organic overall QX. on be the
of continue our be growth a to part International expect story. We to key
capital reinforce Before our we'd In and capital strategy. the revisit our short, allocation moving remains strategy allocation to like on, same.
Taking prioritize QX cash continue have significantly. We recently $XXX repurchases, shares. and our following of million to we One, XXXX, utilize Having to look M&A the X that, we back towards seen X.X we said million in opportunities; and deployed balance opportunity deploy capital to continue to more we buy share second, the actions: patient. to be cash consistently
QX XXXX, have for we shares our another repurchased million. current in fiscal million Second, X.X already $XXX
share of in will Three, his paid recently million rate variable the an repurchase Today, $XXX both $XXX ASR and repayment debt accelerated program; expand interest four, we debt. remarks. and million announced down additional higher we Ryan on
made years ourselves. the start X-plus back biggest we of have of acquisition since Looking the is the pandemic,
ASR over And $X.X deployed repurchases including we M&A on repurchases, opportunities. make that period, today's And QX announcement recent will this $X.X billion $X.X on nearly XXXX. billion share During in billion. our
As you confident very the position ahead. years for see, are can in we our
Rounding our ongoing we portfolio optimized basis. are we allocation out evaluate to future, capital the our on for carefully an ensure discussion
mentioned As in we our a release, result, gears. recently small have as divested our Shifting business. ultrasound SSI
our As hurdles calls, we and to quarter-by-quarter, we business year-by-year, we prior our continue on ever with broadly have shared fundamentals, transformed our prove have macro strengthened strength. present,
more are with any than At in effectively a at company is brands, history. we and guided we've ever time retooled XX-year a passion margins are deepest team competitive our and core, and moats, we our leadership Hologic industry-leading Hologic, promise. strong Today, our strongest, wide and had. the by new fundamentally recapitalized differentiated purpose,
lives healthier day. Our everywhere, every purpose to enable
advantages to like division, products. focus passion Science distinct and and we globally promise, have differentiated the through Across champion provide on by women's health Our products clinically our the Sure, Health of health with Hologic Women's unique Global each our trailblazing elevating care social high-quality women's initiatives created to professionals Index. innovative health
our We ultimately purpose develop our our and meeting leading positions by customers leaning and needs. patients' into proactively
examples highlight X will today. We
leaders but sector women's only automation. in not are health, also we are workflow we First, in leaders
to pressure to deal the challenges, sourcing manage persistent with continue customers costs. efficiently and technicians Our
biopsy of to are few, From As each the only user-friendly dependable and efficient and customers' cumbersome a systems expectations. is our designed workflow labor-intensive transform top the a efficient instrument processes. name Panther solutions easy-to-use workflows. fluid and product at Brevera our to result, manual systems to breast In our
installed than With size Second, foundation more the the across of in in massive bases over footprint world. systems strong sheer provide a and today's installed installed and instruments Diagnostics X,XXX and our worldwide, Breast mammography U.S.. Health XX,XXX Panther
opportunity the and We be laboratories, the have we partners integral to with support. screening hospitals centers
incremental customers For as menu volume. and Panther, add more drive
more to rooted grow in for Health our customers business while operations. also Breast Our continues and same their deeply valuable can business. molecular our be becoming diagnostics to The said more
at our to ability the efficiencies support for step journey, more a clinical a with unique along is We Hologic that continuum. practitioners comfortable each greater technologies patients and patient for in patient's of customers creating across confidence their our operational customers. ourselves increased and care differentiate ecosystem experience, breast integrate our our
yields on to example, flow brand generation. product cash third each our steady in Moving across stable and division, long-standing strong leadership multiple which our lines margins
in statement business. screening, uterine This fibroid testing, We removal. a STI bleeding and each abnormal leaders given breast cancer the significant strong are respective and in cervical and competitors is treatment innovators face we
across scale and the ability leadership industry-leading margins flow. And and business diversified lines business. cash and we turn, our invest grow our Our support to have in further
competitive Hologic continue we each more are to as are new much aim a growth across international and do deliver as stronger today, division company, premier delivering and we growth we consistently strong to Altogether, the differentiated so. emerging and
finish will of some drivers to XXXX. guidance. detail and next will growth Turning Ryan further the business, our on to in I call attention year's the related each high-level with touch
backlog years, expect drive we elevated compared to Diagnostics, confidence First, for future division. In into Health, Breast the year to will in creating our in our of be higher visibility sales, historic Health. molecular strong exciting growth in gantry to XXXX remaining another greater levels, have translating year Breast another gantry growth we pipeline, to with continue as recent for
also to We new add menu continue for installed existing Panther to large increasing expect global while assays. base our volume
is are drive Boulder shine. therapy our is BCI and the guidelines acquired products grew the emerging which continue Surgical likely In XXXX, still growth as more double-digit In of rate. adjuvant molecular In profitable growing to rate. only to beyond which our even XXXX our also drivers. example to acquired to innings being addition, rate strong our Surgical, still and are early test. are newer X Acessa Biotheranostics to projected continues via growth American we patients Surgical innovative international test in benefit U.S. and surgical continue Index Biotheranostics Fluent predict XXXX, recognized of years, the expected business, growth than differentiated we our was growth accretive NCCN MyoSure, growth. Breast and and is clearly delivering the Society In in that growth XX%, yet laparoscopic and from we Clinical extended Oncology a another over by Internationally, double Cancer product. to an to system
To entering we a new XXXX, are Hologic. differentiated conclude, and
are and competitive ever. more than bigger, stronger We
will Our power forward. strong balance leadership profile divisions: brands growth drivers across us X continue durable all sheet to margin and
around an look on the health ahead impact to we are to make continue world. XXXX, we grow women's As bigger poised and even to
With hand to the that, over call Ryan. let me
